Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Characterization of naturally occurring mutations in the envelop of HIV-1 subtype-C that arise during the course of infection and contribute to pathogenesis

EF 2009-10

Résumé
Human immunodeficiency virus (HIV) is an enveloped virus and a member of the retrovirus family that causes acquired immunodeficiency syndrome (AIDS). An estimated 33 million people are living with HIV infection worldwide. One striking feature of this global epidemic is the geographical distribution of different HIV-1 subtypes. Most of the current research regarding HIV-1 pathogenesis has been focused on the study of HIV-1 subtype B (B-HIV), which is predominantly found in western countries. However, more than 50% of all people infected with HIV-1 and 20% of the entire adult population in much of sub-Saharan Africa are infected with subtype C (C-HIV). HIV-1 infects vital cells of our immune system by entering through a receptor called CD4, and a coreceptor, which can be either CCR5 (R5) or CXCR4 (X4). B-HIV has been shown to use both coreceptors although at late stages of infection, it preferentially uses X4. In contrast, C-HIV isolates exclusively use the R5 coreceptor for viral entry. Studies have shown that during B-HIV infections, the viruses that use R5 acquire natural mutations that increase pathogenesis thereby making the patient's illness worse. We believe that C-HIV viruses also acquire mutations during the course of an infection that allows the virus to be more efficient at entering and killing immune cells. To verify our hypothesis, we propose to use a consented cohort of 196 individuals from Zimbabwe with C-HIV. Samples were taken at different times spanning the asymptomatic stages of infection through to AIDS. Using these samples, we will identify naturally occurring changes in the C-HIV envelope and verify how these mutations affect HIV-1 entry and death of immune cells. Our findings will not only be important for better understanding how C-HIV evolves over the course of time but also for the development of novel vaccines and/or entry inhibitors designed to treat the millions of people suffering from C-HIV infection.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Australia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
203045
Name
Rudd Penny A
Country
Australia
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Characterization of naturally occurring mutations in the envelop of HIV-1 subtype-C that arise during the course of infection and contribute to pathogenesis
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Biosafety Level 3 Containment Laboratory; Envelope Glycoproteins; Genetic Analysis; Hiv/Aids; Molecular Virology; Mupfure Schistosomiasis And Hiv Cohort; Pathogenesis; Protein Modeling
Abstract
Human immunodeficiency virus (HIV) is an enveloped virus and a member of the retrovirus family that causes acquired immunodeficiency syndrome (AIDS). An estimated 33 million people are living with HIV infection worldwide. One striking feature of this global epidemic is the geographical distribution of different HIV-1 subtypes. Most of the current research regarding HIV-1 pathogenesis has been focused on the study of HIV-1 subtype B (B-HIV), which is predominantly found in western countries. However, more than 50% of all people infected with HIV-1 and 20% of the entire adult population in much of sub-Saharan Africa are infected with subtype C (C-HIV). HIV-1 infects vital cells of our immune system by entering through a receptor called CD4, and a coreceptor, which can be either CCR5 (R5) or CXCR4 (X4). B-HIV has been shown to use both coreceptors although at late stages of infection, it preferentially uses X4. In contrast, C-HIV isolates exclusively use the R5 coreceptor for viral entry. Studies have shown that during B-HIV infections, the viruses that use R5 acquire natural mutations that increase pathogenesis thereby making the patient's illness worse. We believe that C-HIV viruses also acquire mutations during the course of an infection that allows the virus to be more efficient at entering and killing immune cells. To verify our hypothesis, we propose to use a consented cohort of 196 individuals from Zimbabwe with C-HIV. Samples were taken at different times spanning the asymptomatic stages of infection through to AIDS. Using these samples, we will identify naturally occurring changes in the C-HIV envelope and verify how these mutations affect HIV-1 entry and death of immune cells. Our findings will not only be important for better understanding how C-HIV evolves over the course of time but also for the development of novel vaccines and/or entry inhibitors designed to treat the millions of people suffering from C-HIV infection.
Competitiondate
201002
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Rudd, Penny A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~